

Special Issue

Advances in Macrophage-Based Immunotherapy

Message from the Guest Editor

Adoptive cellular therapies are making major strides in the treatment of many diseases, especially in cancer and fibrosis. Amongst cell types used in immunotherapies, macrophages are prominent candidates. Macrophages have critical functions in both innate and adaptive immune responses. They are present in almost every tissue, recognize exogenous/endogenous danger signals through pattern-recognition receptors, produce cytokines/chemokines that orchestrate immune responses, function as professional antigen-presenting cells, and are important elements in wound repair and fibrosis by regulating extracellular matrix turnover. The diversity of functions they perform is due to the fact that their phenotype is highly plastic and exists across a spectrum of pro- and anti-inflammatory states. The Special Issue “Advanced in Macrophage-Based Immunotherapy” aims to collect information on the use of cell therapy in different pathologies, with a special interest in therapy that uses reprogrammed macrophages capable of limiting the pathology by modifying the microenvironment, favoring the cleaning of cancer and fibrotic cells or promoting regeneration, among other processes.

Guest Editor

Prof. Dr. Dolores Ortiz-Masiá

1. Departamento de Medicina, Facultad de Medicina, Universidad de Valencia, 46010 Valencia, Spain
2. Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), 46010 Valencia, Spain

Deadline for manuscript submissions

30 April 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/145480

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).